Richard Farlie

Dr. Richard Farlie

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2021 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
AAAnna J. M. Aabakke
Anna J. M. Aabakke
LKLone Krebs
Lone Krebs
TPTanja G. Petersen
Tanja G. Petersen
FKFrank S. Kjeldsen
Frank S. Kjeldsen
GCGiulia Corn
Giulia Corn
MBMette Bliddal
Mette Bliddal
Introduction: Assessing the risk factors for and consequences of infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) during pregnancy is essential to guide clinical care. Previous studies on SARS‐CoV‐2 infection in pregnancy have been among hospitalized patients, which may have exaggerated risk estimates of severe outcomes because all cases of SARS‐CoV‐2 infection in the pregnant population were not included. The objectives of this study were to identify risk factors for and outcomes after SARS‐CoV‐2 infection in pregnancy independent of severity of infection in a universally tested population, and to identify risk factors for and outcomes after severe infection requiring hospital admission.Material and methods: This was a prospective population‐based cohort study in Denmark using data from the Danish National Patient Register and Danish Microbiology Database and prospectively registered data from medical records. We included all pregnancies between March 1 and October 31, 2020 and compared women with a positive SARS‐CoV‐2 test during pregnancy to non‐infected pregnant women. Cases of SARS‐CoV‐2 infection in pregnancy were both identified prospectively and through register linkage to ensure that all cases were identified and that cases were pregnant during infection. Main outcome measures were pregnancy, delivery, maternal, and neonatal outcomes. Severe infection was defined as hospital admission due to coronavirus disease 2019 (COVID‐19) symptoms.Results: Among 82 682 pregnancies, 418 women had SARS‐CoV‐2 infection during pregnancy, corresponding to an incidence of 5.1 per 1000 pregnancies, 23 (5.5%) of which required hospital admission due to COVID‐19. Risk factors for infection were asthma (odds ratio [OR] 2.19, 95% CI 1.41–3.41) and being foreign born (OR 2.12, 95% CI 1.70–2.64). Risk factors for hospital admission due to COVID‐19 included obesity (OR 2.74, 95% CI 1.00–7.51), smoking (OR 4.69, 95% CI 1.58–13.90), infection after gestational age (GA) 22 weeks (GA 22–27 weeks: OR 3.77, 95% CI 1.16–12.29; GA 28–36 weeks: OR 4.76, 95% CI 1.60–14.12), and having asthma (OR 4.53, 95% CI 1.39–14.79). We found no difference in any obstetrical or neonatal outcomes.Conclusions: Only 1 in 20 women with SARS‐CoV‐2 infection during pregnancy required admission to hospital due to COVID‐19. Risk factors for admission comprised obesity, smoking, asthma, and infection after GA 22 weeks. Severe adverse outcomes of SARS‐CoV‐2 infection in pregnancy were rare.

1 January 1998
Verified
Journal Article
Closed access
RFRichard Farlie
Richard Farlie
AJAnne Marie Bak Jylling
Anne Marie Bak Jylling
MVMax Vetner
Max Vetner

7 March 2021 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Open access
PDF file
CTChristian Liebst Frisk Toft
Christian Liebst Frisk Toft
HIHans Jakob Ingerslev
Hans Jakob Ingerslev
Ulrik Schiøler KesmodelUlrik Schiøler Kesmodel
Ulrik Schiøler Kesmodel
LHLotte Hatt
Lotte Hatt
RSRipudaman Singh
Ripudaman Singh
IPInge Søkilde Pedersen
Inge Søkilde Pedersen
Purpose: Proof of concept of the use of cell-based non-invasive prenatal testing (cbNIPT) as an alternative to chorionic villus sampling (CVS) following preimplantation genetic testing for monogenic disorders (PGT-M). Method: PGT-M was performed by combined testing of short tandem repeat (STR) markers and direct mutation detection, followed by transfer of an unaffected embryo. Patients who opted for follow-up of PGT-M by CVS had blood sampled, from which potential fetal extravillous throphoblast cells were isolated. The cell origin and mutational status were determined by combined testing of STR markers and direct mutation detection using the same setup as during PGT. The cbNIPT results with respect to the mutational status were compared to those of genetic testing of the CVS. Results: Eight patients had blood collected between gestational weeks 10 and 13, from which 33 potential fetal cell samples were isolated. Twenty-seven out of 33 isolated cell samples were successfully tested (82%), of which 24 were of fetal origin (89%). This corresponds to a median of 2.5 successfully tested fetal cell samples per case (range 1–6). All fetal cell samples had a genetic profile identical to that of the transferred embryo confirming a pregnancy with an unaffected fetus, in accordance with the CVS results. Conclusion: These findings show that although measures are needed to enhance the test success rate and the number of cells identified, cbNIPT is a promising alternative to CVS. Trial registration number: N-20180001

17 February 2010 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
FLFinn Friis Lauszus
Finn Friis Lauszus
JNJacob Lauesgaard Nielsen
Jacob Lauesgaard Nielsen
JBJane Boelskifte
Jane Boelskifte
JFJørgen Falk
Jørgen Falk
RFRichard Farlie
Richard Farlie
KRKjeld Leisgård Rasmussen
Kjeld Leisgård Rasmussen

Verified
Journal Article
Open access
PDF file
LFLine Fich
Line Fich
ACAnn-Marie Hellerung Christiansen
Ann-Marie Hellerung Christiansen
KHKathrine Vauvert R. Hviid
Kathrine Vauvert R. Hviid
AAAnna J. M. Aabakke
Anna J. M. Aabakke
EHEva Hoffmann
Eva Hoffmann
HNHenriette Svarre Nielsen
Henriette Svarre Nielsen
Passive maternal-fetal transfer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies has been demonstrated, whilst the degree of transfer depending on the trimester of infection is lacking. Due to neonates’ immature immune systems, this knowledge could be of interest when investigating the degree of early-life protection against SARS-CoV-2. For perinatal infections such as Rubella and Toxoplasmosis, the timing of infection related to gestational age is crucial for the severity of maternal-fetal outcomes; hence, the trimester of SARS-CoV-2 infection could potentially be crucial. So far, there is no stratification on all three trimesters of SARS-CoV-2 infection in relation to maternal antibody levels in SARS-CoV-2 positive women, and the degree of transfer of SARS-CoV-2 antibodies to the newborn nor on obstetric and neonatal outcomes, which we examined in this study. Eleven departments in Denmark invited women who tested SARS-CoV-2 positive during pregnancy to participate with a blood sample and a cord blood sample at delivery. 459 SARS-CoV-2 positive women and 2567 SARS-CoV-2 negative women were included. A percentage of 87.5%, 95.3%, and 60.3% of newborns of women who tested positive in their first, second, and third trimester, respectively, had a significantly higher immunoglobin G (IgG) antibody level than their mother at delivery, indicating that the fetus is able to concentrate antibody levels or maintain the level of IgG antibodies transferred. None of the examined maternal-fetal outcomes were increased in women infected with SARS-CoV-2.

1 January 2007
Verified
Journal Article
Closed access
NBNiels Boye
Niels Boye
FEFrey Eberholst
Frey Eberholst
RFRichard Farlie
Richard Farlie
LSLene B Sørensen
Lene B Sørensen
KLKaren Marie Lyng
Karen Marie Lyng